Yang Junzhi, Betterton Robert D, Williams Erica I, Stanton Joshua A, Reddell Elizabeth S, Ogbonnaya Chidinma E, Dorn Emma, Davis Thomas P, Lochhead Jeffrey J, Ronaldson Patrick T
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Pharmaceutics. 2022 Apr 27;14(5):949. doi: 10.3390/pharmaceutics14050949.
The consumption of acetaminophen (APAP) can induce neurological changes in human subjects; however, effects of APAP on blood-brain barrier (BBB) integrity are unknown. BBB changes by APAP can have profound consequences for brain delivery of co-administered drugs. To study APAP effects, female Sprague-Dawley rats (12-16 weeks old) were administered vehicle (i.e., 100% dimethyl sulfoxide (DMSO), intraperitoneally (i.p.)) or APAP (80 mg/kg or 500 mg/kg in DMSO, i.p.; equivalent to a 900 mg or 5600 mg daily dose for a 70 kg human subject). BBB permeability was measured via in situ brain perfusion using [C]sucrose and [H]codeine, an opioid analgesic drug that is co-administered with APAP (i.e., Tylenol #3). Localization and protein expression of tight junction proteins (i.e., claudin-5, occludin, ZO-1) were studied in rat brain microvessels using Western blot analysis and confocal microscopy, respectively. Paracellular [C]sucrose "leak" and brain [H]codeine accumulation were significantly enhanced in rats treated with 500 mg/kg APAP only. Additionally, claudin-5 localization and protein expression were altered in brain microvessels isolated from rats administered 500 mg/kg APAP. Our novel and translational data show that BBB integrity is altered following a single high APAP dose, results that are relevant to patients abusing or misusing APAP and/or APAP/opioid combination products.
对乙酰氨基酚(APAP)的摄入可在人体受试者中诱发神经学变化;然而,APAP对血脑屏障(BBB)完整性的影响尚不清楚。APAP引起的BBB变化可能会对同时给药药物的脑内递送产生深远影响。为了研究APAP的作用,给雌性Sprague-Dawley大鼠(12 - 16周龄)腹腔注射赋形剂(即100%二甲基亚砜(DMSO))或APAP(80 mg/kg或500 mg/kg溶于DMSO中,腹腔注射;相当于70 kg人类受试者每日900 mg或5600 mg的剂量)。通过使用[C]蔗糖和[H]可待因的原位脑灌注来测量BBB通透性,[H]可待因是一种与APAP(即泰诺#3)同时给药的阿片类镇痛药。分别使用蛋白质印迹分析和共聚焦显微镜在大鼠脑微血管中研究紧密连接蛋白(即claudin-5、闭合蛋白、ZO-1)的定位和蛋白表达。仅在接受500 mg/kg APAP治疗的大鼠中,细胞旁[C]蔗糖“渗漏”和脑内[H]可待因蓄积显著增强。此外,从接受500 mg/kg APAP治疗的大鼠分离出的脑微血管中,claudin-5的定位和蛋白表达发生了改变。我们新的转化医学数据表明,单次高剂量APAP后BBB完整性会发生改变,这些结果与滥用或误用APAP和/或APAP/阿片类联合产品的患者相关。